Formulation Development Outsourcing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Service (Pre-formulation, Formulation Development); By Formulation (Topical, Oral, Injectable); By Therapeutic Area (

Formulation Development Outsourcing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Service (Pre-formulation, Formulation Development); By Formulation (Topical, Oral, Injectable); By Therapeutic Area (Oncology, Infectious Disease, Respiratory, Cardiovascular, Neurology, Hematology, Dermatology); By End User (Pharmaceutical Industries, Research & Academic Institutions); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)


Global Formulation Development Outsourcing Market Size Set to Touch USD 36.5 Billion by 2029

Global formulation development outsourcing market is flourishing because of an increasing demand for novel medications and focus on cost efficiency.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global formulation development outsourcing market size at USD 24.27 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global formulation development outsourcing market size to grow at a significant CAGR of 7.03% reaching a value of USD 36.48 billion by 2029. Major growth drivers for the global formulation development outsourcing market include the rising research and development (R&D) costs, a growing need for specialized expertise, and the pursuit of cost savings. Many pharmaceutical companies are turning to outsourcing due to time constraints and limited internal resources, which offers advantages, such as faster project timelines, access to specialized knowledge, and better protection against subpar products. This trend is particularly pronounced among drug developers, with a growing interest in outsourcing formulation development and manufacturing, especially in emerging economies like India. The demand for innovative medications, driven by the significant burden of infectious and chronic diseases, is a primary catalyst for the sector's growth. Also, the industry's focus on improving the solubility of poorly water-soluble compounds and patent expirations has fueled outsourcing. The urgency brought on by the COVID-19 pandemic has led to substantial investments in R&D, further boosting market growth. Rising R&D expenses are expected to drive the demand for formulation development outsourcing, particularly among smaller pharmaceutical companies without in-house capabilities. The industry's increasing collaboration with academic institutions is also contributing to the expansion of this outsourcing sector. However, data security and confidentiality concerns and quality control are anticipated to restrain the overall market growth during the forecast period.

Global Formulation Development Outsourcing Market – Overview

The global formulation development outsourcing market refers to the sector within the pharmaceutical and biotechnology industries where companies contract out the process of developing and optimizing the formulation of new drug products to specialized external service providers. This outsourcing typically involves tasks such as pre-formulation studies, formulation design, analytical testing, and sometimes the production of clinical trial materials. The primary objective of outsourcing formulation development is to leverage the expertise, resources, and infrastructure of Contract Development and Manufacturing Organizations (CDMOs) or other specialized firms to streamline drug development processes, reduce costs, accelerate time-to-market, and ensure compliance with regulatory requirements. It is a strategic approach utilized by pharmaceutical companies to efficiently navigate the complex and highly regulated landscape of drug formulation, allowing them to focus on core research and development activities while benefiting from external expertise and capabilities.

Impact of COVID-19 on Global Formulation Development Outsourcing Market

COVID-19 pandemic had a mixed impact on the global formulation development outsourcing market. While it accelerated the need for vaccine and therapeutic development, leading to increased outsourcing in certain segments, disruptions in supply chains and clinical trials caused delays in some projects. The pandemic underscored the importance of formulation development and highlighted the industry's adaptability. Furthermore, the pharmaceutical sector faced heightened scrutiny in terms of regulatory compliance and data security during remote work. As the pandemic subsided, the market continued to evolve, with companies increasingly relying on outsourcing for flexibility, cost-effectiveness, and specialized expertise in drug formulation.

Global Formulation Development Outsourcing Market – By Therapeutic Area

Based on therapeutic area, the global formulation development outsourcing market is divided into Oncology, Infectious Disease, Respiratory, Cardiovascular, Neurology, Hematology, and Dermatology segments. The oncology segment dominates the global formulation development outsourcing market by therapeutic area. Oncology drugs are inherently complex, often requiring specialized formulations for effective delivery. The pursuit of novel therapies, increasing prevalence of cancer worldwide, and rapid advancements in oncology research have fueled the demand for formulation expertise. Pharmaceutical companies prefer outsourcing to specialized partners with proven capabilities in oncology formulation development, as it streamlines the development process, expedites regulatory approvals, and ensures optimal drug delivery. Consequently, the oncology sector's complexity and growth potential make it a dominant force in the formulation development outsourcing market.

Competitive Landscape

Major players operating in the global formulation development outsourcing market include Aizant Drug Research Solutions Private Limited, Catalent Inc., Charles River Laboratories, Dr. Reddy’s Laboratories Ltd, Emergent BioSolutions Inc., Intertek Group plc, Irisys LLC (Recro Pharma), Laboratory Corporation of America Holdings, Lonza Group AG, Piramal Pharma Solutions, Quotient Sciences, Syngene International Limited (Biocon Limited), and Thermo Fisher Scientific Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Formulation Development Outsourcing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Formulation Development Outsourcing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.


1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Formulation Development Outsourcing Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising demand for novel medications
3.2.1.2. Cost efficiency
3.2.2. Restraints
3.2.2.1. Data security and confidentiality concerns
3.2.2.2. Quality control
3.2.3. Opportunities
3.2.3.1. Market expansion
3.2.3.2. Diversification
3.2.4. Challenges
3.2.4.1. Regulatory compliance
3.2.4.2. Competition
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Formulation Development Outsourcing Market Overview
4.1. Market Size & Forecast, 2019–2029
4.1.1. By Value (USD Billion)
4.2. Market Share and Forecast
4.2.1. By Service
4.2.1.1. Pre-formulation
4.2.1.2. Formulation Development
4.2.2. By Formulation
4.2.2.1. Topical
4.2.2.2. Oral
4.2.2.3. Injectable
4.2.2.4. Others
4.2.3. By Therapeutic Area
4.2.3.1. Oncology
4.2.3.2. Infectious Disease
4.2.3.3. Respiratory
4.2.3.4. Cardiovascular
4.2.3.5. Neurology
4.2.3.6. Hematology
4.2.3.7. Dermatology
4.2.3.8. Others
4.2.4. By End User
4.2.4.1. Pharmaceutical Industries
4.2.4.2. Research & Academic Institutions
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia Pacific (APAC)
4.2.5.4. Latin America (LATAM)
4.2.5.5. Middle East and Africa (MEA)
5. North America Formulation Development Outsourcing Market
5.1. Market Size & Forecast, 2019–2029
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Service
5.2.2. By Formulation
5.2.3. By Therapeutic Area
5.2.4. By End User
5.2.5. By Country
5.2.5.1. United States
5.2.5.1.1. By Service
5.2.5.1.2. By Formulation
5.2.5.1.3. By Therapeutic Area
5.2.5.1.4. By End User
5.2.5.2. Canada
5.2.5.2.1. By Service
5.2.5.2.2. By Formulation
5.2.5.2.3. By Therapeutic Area
5.2.5.2.4. By End User
6. Europe Formulation Development Outsourcing Market
6.1. Market Size & Forecast, 2019–2029
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Service
6.2.2. By Formulation
6.2.3. By Therapeutic Area
6.2.4. By End User
6.2.5. By Country
6.2.5.1. Germany
6.2.5.1.1. By Service
6.2.5.1.2. By Formulation
6.2.5.1.3. By Therapeutic Area
6.2.5.1.4. By End User
6.2.5.2. United Kingdom
6.2.5.2.1. By Service
6.2.5.2.2. By Formulation
6.2.5.2.3. By Therapeutic Area
6.2.5.2.4. By End User
6.2.5.3. Italy
6.2.5.3.1. By Service
6.2.5.3.2. By Formulation
6.2.5.3.3. By Therapeutic Area
6.2.5.3.4. By End User
6.2.5.4. France
6.2.5.4.1. By Service
6.2.5.4.2. By Formulation
6.2.5.4.3. By Therapeutic Area
6.2.5.4.4. By End User
6.2.5.5. Spain
6.2.5.5.1. By Service
6.2.5.5.2. By Formulation
6.2.5.5.3. By Therapeutic Area
6.2.5.5.4. By End User
6.2.5.6. Belgium
6.2.5.6.1. By Service
6.2.5.6.2. By Formulation
6.2.5.6.3. By Therapeutic Area
6.2.5.6.4. By End User
6.2.5.7. Russia
6.2.5.7.1. By Service
6.2.5.7.2. By Formulation
6.2.5.7.3. By Therapeutic Area
6.2.5.7.4. By End User
6.2.5.8. The Netherlands
6.2.5.8.1. By Service
6.2.5.8.2. By Formulation
6.2.5.8.3. By Therapeutic Area
6.2.5.8.4. By End User
6.2.5.9. Rest of Europe
6.2.5.9.1. By Service
6.2.5.9.2. By Formulation
6.2.5.9.3. By Therapeutic Area
6.2.5.9.4. By End User
7. Asia-Pacific Formulation Development Outsourcing Market
7.1. Market Size & Forecast, 2019–2029
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Service
7.2.2. By Formulation
7.2.3. By Therapeutic Area
7.2.4. By End User
7.2.5. By Country
7.2.5.1. China
7.2.5.1.1. By Service
7.2.5.1.2. By Formulation
7.2.5.1.3. By Therapeutic Area
7.2.5.1.4. By End User
7.2.5.2. India
7.2.5.2.1. By Service
7.2.5.2.2. By Formulation
7.2.5.2.3. By Therapeutic Area
7.2.5.2.4. By End User
7.2.5.3. Japan
7.2.5.3.1. By Service
7.2.5.3.2. By Formulation
7.2.5.3.3. By Therapeutic Area
7.2.5.3.4. By End User
7.2.5.4. South Korea
7.2.5.4.1. By Service
7.2.5.4.2. By Formulation
7.2.5.4.3. By Therapeutic Area
7.2.5.4.4. By End User
7.2.5.5. Australia & New Zealand
7.2.5.5.1. By Service
7.2.5.5.2. By Formulation
7.2.5.5.3. By Therapeutic Area
7.2.5.5.4. By End User
7.2.5.6. Indonesia
7.2.5.6.1. By Service
7.2.5.6.2. By Formulation
7.2.5.6.3. By Therapeutic Area
7.2.5.6.4. By End User
7.2.5.7. Malaysia
7.2.5.7.1. By Service
7.2.5.7.2. By Formulation
7.2.5.7.3. By Therapeutic Area
7.2.5.7.4. By End User
7.2.5.8. Singapore
7.2.5.8.1. By Service
7.2.5.8.2. By Formulation
7.2.5.8.3. By Therapeutic Area
7.2.5.8.4. By End User
7.2.5.9. Vietnam
7.2.5.9.1. By Service
7.2.5.9.2. By Formulation
7.2.5.9.3. By Therapeutic Area
7.2.5.9.4. By End User
7.2.5.10. Rest of APAC
7.2.5.10.1. By Service
7.2.5.10.2. By Formulation
7.2.5.10.3. By Therapeutic Area
7.2.5.10.4. By End User
8. Latin America Formulation Development Outsourcing Market
8.1. Market Size & Forecast, 2019–2029
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Service
8.2.2. By Formulation
8.2.3. By Therapeutic Area
8.2.4. By End User
8.2.5. By Country
8.2.5.1. Brazil
8.2.5.1.1. By Service
8.2.5.1.2. By Formulation
8.2.5.1.3. By Therapeutic Area
8.2.5.1.4. By End User
8.2.5.2. Mexico
8.2.5.2.1. By Service
8.2.5.2.2. By Formulation
8.2.5.2.3. By Therapeutic Area
8.2.5.2.4. By End User
8.2.5.3. Argentina
8.2.5.3.1. By Service
8.2.5.3.2. By Formulation
8.2.5.3.3. By Therapeutic Area
8.2.5.3.4. By End User
8.2.5.4. Peru
8.2.5.4.1. By Service
8.2.5.4.2. By Formulation
8.2.5.4.3. By Therapeutic Area
8.2.5.4.4. By End User
8.2.5.5. Rest of LATAM
8.2.5.5.1. By Service
8.2.5.5.2. By Formulation
8.2.5.5.3. By Therapeutic Area
8.2.5.5.4. By End User
9. Middle East & Africa Formulation Development Outsourcing Market
9.1. Market Size & Forecast, 2019–2029
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Service
9.2.2. By Formulation
9.2.3. By Therapeutic Area
9.2.4. By End User
9.2.5. By Country
9.2.5.1. Saudi Arabia
9.2.5.1.1. By Service
9.2.5.1.2. By Formulation
9.2.5.1.3. By Therapeutic Area
9.2.5.1.4. By End User
9.2.5.2. UAE
9.2.5.2.1. By Service
9.2.5.2.2. By Formulation
9.2.5.2.3. By Therapeutic Area
9.2.5.2.4. By End User
9.2.5.3. Qatar
9.2.5.3.1. By Service
9.2.5.3.2. By Formulation
9.2.5.3.3. By Therapeutic Area
9.2.5.3.4. By End User
9.2.5.4. Kuwait
9.2.5.4.1. By Service
9.2.5.4.2. By Formulation
9.2.5.4.3. By Therapeutic Area
9.2.5.4.4. By End User
9.2.5.5. South Africa
9.2.5.5.1. By Service
9.2.5.5.2. By Formulation
9.2.5.5.3. By Therapeutic Area
9.2.5.5.4. By End User
9.2.5.6. Nigeria
9.2.5.6.1. By Service
9.2.5.6.2. By Formulation
9.2.5.6.3. By Therapeutic Area
9.2.5.6.4. By End User
9.2.5.7. Algeria
9.2.5.7.1. By Service
9.2.5.7.2. By Formulation
9.2.5.7.3. By Therapeutic Area
9.2.5.7.4. By End User
9.2.5.8. Rest of MEA
9.2.5.8.1. By Service
9.2.5.8.2. By Formulation
9.2.5.8.3. By Therapeutic Area
9.2.5.8.4. By End User
10. Competitive Landscape
10.1. List of Key Players and Their Services
10.2. Global Formulation Development Outsourcing Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Formulation Development Outsourcing Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
12.1. Aizant Drug Research Solutions Private Limited
12.2. Catalent Inc.
12.3. Charles River Laboratories
12.4. Dr. Reddy’s Laboratories Ltd.
12.5. Emergent BioSolutions Inc.
12.6. Intertek Group plc
12.7. Irisys LLC (Recro Pharma)
12.8. Laboratory Corporation of America Holdings
12.9. Lonza Group AG
12.10. Piramal Pharma Solutions
12.11. Quotient Sciences
12.12. Syngene International Limited (Biocon Limited)
12.13. Thermo Fisher Scientific Inc.
12.14. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings